UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies

Journal of general internal medicine : JGIM, 2024-09, Vol.39 (12), p.2187-2195

2024

Volltextzugriff (PDF)

Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study

Archives of dermatological research, 2024-05, Vol.316 (5), p.154-154, Article 154

2024

Volltextzugriff (PDF)

Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey

Journal of general internal medicine : JGIM, 2016-06, Vol.31 (6), p.609-614

2016

Volltextzugriff (PDF)

Evaluation of the Generic Drug User Fee Act (GDUFA) Program for Fiscal Years 2013–2022

The AAPS journal, 2024-07, Vol.26 (5), p.85, Article 85

2024

Volltextzugriff (PDF)

The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products

Archives of Dermatological Research, 2020-10, Vol.312 (8), p.559-565

2020

Volltextzugriff (PDF)

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

Annals of hematology, 2015-04, Vol.94 (Suppl 2), p.249-257

2015

Volltextzugriff (PDF)

Strategies to Reduce Out-of-Pocket Medication Costs for Canadians Living with Heart Failure

Cardiovascular drugs and therapy, 2021-10, Vol.35 (5), p.1009-1023

2021

Volltextzugriff (PDF)

Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin

Current diabetes reports, 2020-01, Vol.20 (1), p.2-2, Article 2

2020

Volltextzugriff (PDF)

A reappraisal of generic bisphosphonates in osteoporosis

Osteoporosis international, 2012-01, Vol.23 (1), p.213-221

2012

Volltextzugriff (PDF)

Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects

The AAPS journal, 2015-09, Vol.17 (5), p.1312-1316

2015

Volltextzugriff (PDF)

A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction

The European journal of health economics, 2020-02, Vol.21 (1), p.73-84

2020

Volltextzugriff (PDF)

Access to and Use of $4 Generic Programs in Medicare

Journal of general internal medicine : JGIM, 2012-10, Vol.27 (10), p.1251-1257

2012

Volltextzugriff (PDF)

The diffusion of generics after patent expiry in Germany

The European journal of health economics, 2016-11, Vol.17 (8), p.1027-1040

2016

Volltextzugriff (PDF)

Patient Co-payment and Adherence to Statins: A Review and Case Studies

Cardiovascular drugs and therapy, 2014-02, Vol.28 (1), p.99-109

2014

Volltextzugriff (PDF)

Compulsory licensing and access to drugs

The European journal of health economics, 2015-01, Vol.16 (1), p.83-94

2015

Volltextzugriff (PDF)

Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences

European journal of clinical pharmacology, 2011-01, Vol.67 (1), p.33-38

2011

Volltextzugriff (PDF)

Defining High Risk: Cost-Effectiveness of Extended-Duration Thromboprophylaxis Following Major Oncologic Abdominal Surgery

Journal of gastrointestinal surgery, 2014-01, Vol.18 (1), p.60-68

2014

Volltextzugriff (PDF)

Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future

International journal of clinical pharmacy, 2015-02, Vol.37 (1), p.12-17

2015

Volltextzugriff (PDF)

Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use

Journal of general internal medicine : JGIM, 2007-09, Vol.22 (9), p.1298-1304

2007

Volltextzugriff (PDF)

What's in a name? Use of brand versus generic drug names in United States outpatient practice

Journal of general internal medicine : JGIM, 2007-05, Vol.22 (5), p.645-648

2007

Volltextzugriff (PDF)

Potential Savings Associated with Drug Substitution in Medicare Part D: The Translating Research into Action for Diabetes (TRIAD) Study

Journal of general internal medicine : JGIM, 2014-01, Vol.29 (1), p.230-236

2014

Volltextzugriff (PDF)

What is the value of ‘me-too’ drugs?

Health care management science, 2013-12, Vol.16 (4), p.300-313

Régnier, Stephane

2013

Volltextzugriff (PDF)

Requirements for generic antiepileptic medicines: a clinical perspective

Journal of neurology, 2011-12, Vol.258 (12), p.2128-2132

2011

Volltextzugriff (PDF)

Western European markets for biosimilar and generic drugs: worth differentiating

The European journal of health economics, 2015-09, Vol.16 (7), p.683-687

2015

Volltextzugriff (PDF)

The Impact of the Medicare Part D Prescription Benefit on Generic Drug Use

Journal of general internal medicine : JGIM, 2008-10, Vol.23 (10), p.1673-1678

2008

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Aktive Filter

KollektionSpringerLINK Contemporary (Konsortium Baden-Württemberg)

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(135)
Mit Volltextzugriff
(147)

Publikationsform

Artikel
(148)

Sprache

Englisch
(133)
Deutsch
(15)

Erscheinungsjahr

n.n

Thema

Humans
(103)
Science & Technology
(102)
Life Sciences & Biomedicine
(99)
Generic Drugs
(87)
Medicine
(76)
Medicine & Public Health
(75)
Drugs, Generic - Economics
(71)
Economics
(65)
Social Sciences
(64)
Business & Economics
(61)
Prescription Drugs
(55)
Health Care Sciences & Services
(53)
Chemicals, Rubber, Drugs, Biotechnology, Plastics
(51)
Drugs
(47)
Studies
(47)
Health Economics
(46)
Pharmaceutical Industry
(46)
Public Health
(44)
Health Policy & Services
(40)
Prices
(39)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Availability and Cost of Expensive and Common Generic Prescription Drugs: A Cross-sectional Analysis of Direct-to-Consumer Pharmacies

Effectiveness and safety of generic tofacitinib in alopecia areata: is the generic a cost-effective option? A retrospective study

Variations in Patients' Perceptions and Use of Generic Drugs: Results of a National Survey

Evaluation of the Generic Drug User Fee Act (GDUFA) Program for Fiscal Years 2013–2022

The relationship between the number of available therapeutic options and government payer (medicare part D) spending on topical drug products

Changing the cost of care for chronic myeloid leukemia: the availability of generic imatinib in the USA and the EU

Strategies to Reduce Out-of-Pocket Medication Costs for Canadians Living with Heart Failure

Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin

A reappraisal of generic bisphosphonates in osteoporosis

Regulation of Generic Drugs in Japan: the Current Situation and Future Prospects

A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction

Access to and Use of $4 Generic Programs in Medicare

The diffusion of generics after patent expiry in Germany

Patient Co-payment and Adherence to Statins: A Review and Case Studies

Compulsory licensing and access to drugs

Norwegian patients on generic antihypertensive drugs: a qualitative study of their own experiences

Defining High Risk: Cost-Effectiveness of Extended-Duration Thromboprophylaxis Following Major Oncologic Abdominal Surgery

Medicine prices, availability, and affordability in the Shaanxi Province in China: implications for the future

Patient, physician, pharmacy, and pharmacy benefit design factors related to generic medication use

What's in a name? Use of brand versus generic drug names in United States outpatient practice

Potential Savings Associated with Drug Substitution in Medicare Part D: The Translating Research into Action for Diabetes (TRIAD) Study

What is the value of ‘me-too’ drugs?

Requirements for generic antiepileptic medicines: a clinical perspective

Western European markets for biosimilar and generic drugs: worth differentiating

The Impact of the Medicare Part D Prescription Benefit on Generic Drug Use

Aktive Filter

Suchergebnisse filtern